

Title: Novel Approaches for HR+/HER2-Negative Advanced Breast Cancer: Making Informed Clinical Decisions for Your Patients

Dates: Live activities held September 28, 2016, October 11, 2016, November 16, 2016, November 17, 2016, November 22, 2016, December 6, 2016 and December 16, 2016

Locations: Alexandria, Virginia; San Antonio, Texas; New Smyrna Beach, Florida; Chicago, Illinois; Ocala, Florida; Billings, Montana; and Washington, D.C.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Evaluate current guidelines for making treatment choices for patients with HR-positive advanced breast cancer in the first- and second-line settings
- Interpret current and emerging clinical data on the efficacy and safety of treatment options for HR-positive advanced breast cancer in the first- and second-line settings
- Examine current data and rationale for therapeutic strategies regarding the mechanisms of endocrine resistance
- Explain how to integrate new agents into the treatment paradigm for managing HR-positive advanced breast cancer in the first- and second-line settings

Target Audience

This activity is designed for medical oncologists, radiation oncologists, pathologists and other healthcare providers who treat advanced breast cancer.

Program Overview

The goal of this activity is to provide medical oncologists, radiation oncologists, pathologists and other healthcare providers with an understanding of the latest clinical advances and emerging data to enhance clinical decision-making to ultimately improve outcomes in patients with hormone receptor–positive advanced breast cancer.

Faculty

Harold J. Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Brigham & Women's Hospital
Boston, Massachusetts

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and AXIS Medical Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Clinical and Patient Educators Association designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CLINICAL & PATIENT EDUCATORS ASSOCIATION

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Genentech.